CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052024 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nupur Khunti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Cancer Research, Ulm University Medical Center, 89081 Ulm, Germany. Hauptthemen laut MEDLINE: Receptors, CXCR4, Antigens, CD19, Antibodies, Monoclonal, Lymphoma, B-Cell. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fritz Thyssen Stiftung, Deutsche Forschungsgemeinschaft, Fritz Thyssen Stiftung (FTS) project.
Abstract (Originalsprache)
CD19 and CXCR4 are pivotal regulators of B-cell activation and migration, respectively. Specifically, CXCR4 signaling critically influences the dissemination of various malignant B cells through constitutive activation and aberrant expression. This study explores the interaction between CD19 and CXCR4 signaling in the context of B-cell lymphomas, particularly focusing on diffuse large B-cell lymphoma (DLBCL) and Waldenström Macroglobulinemia (WM). We assessed the roles of CD19 in survival and CXCL12-induced migration by using knockout (KO) cells of DLBCL and WM origin alongside evaluating the impact of CD19 monoclonal antibodies (mAbs) on antibody-dependent cell-mediated cytotoxicity (ADCC). Our results highlight that CD19 is important for survival and CXCL12-induced migration, and mAbs variably increase CXCL12-induced migration and enhance ADCC. Additionally, we demonstrate that the endogenous peptide inhibitor of the CXCR4 (EPI-X4) derivative JM#21 effectively inhibits CD19-mediated migration enhancement and promotes ADCC, thereby augmenting the therapeutic efficacy of CD19 mAb-based immunotherapy in lymphoma models. Our study underscores the potential of targeting both CD19 and CXCR4 to refine therapeutic strategies for treating B-cell malignancies, suggesting a synergistic approach could improve clinical outcomes in WM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Experimental Cancer Research, Ulm University Medical Center, 89081 Ulm, Germany.
- Institute of Immunology, Ulm University Medical Center, 89081 Ulm, Germany.
- Institute of Microbiology and Hygiene, Ulm University Medical Center, 89081 Ulm, Germany.
- Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.
ORCID-Profile: Moumita Datta, Mirja Harms, Frank Kirchhoff, Jan Münch, Palash Chandra Maity
Förderung
- Fritz Thyssen Stiftung
- Deutsche Forschungsgemeinschaft
- Fritz Thyssen Stiftung (FTS) project
- Ulm University Bausteinprogramm
- Baden-Württemberg Foundation
Zitieren
APA
Khunti, N., Kumar, M., Datta, M., Harelimana, J. D., Harms, M., Albers, D., Kirchhoff, F., Münch, J., Stenger, S., Buske, C., & Maity, P. C. (2025). CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052024
Vancouver
Khunti N, Kumar M, Datta M, Harelimana JD, Harms M, Albers D, et al. CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052024
BibTeX
@article{Khunti2025,
author = {Khunti, Nupur and Kumar, Manish and Datta, Moumita and Harelimana, Jean de Dieu and Harms, Mirja and Albers, Dan and Kirchhoff, Frank and Münch, Jan and Stenger, Steffen and Buske, Christian and Maity, Palash Chandra},
title = {CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052024}
}
EUVIMED